Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.54 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.50 |
| ▸ | FAAH | O00519 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.41 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19138205 | 1.00 | SLC6A5 (0.54) | SLC6A5NOD1ITGB3ITGA2BFAAH | |
| SCHEMBL19138227 | 1.00 | SLC6A5 (0.54) | SLC6A5NOD1ITGB3ITGA2BFAAH | |
| SCHEMBL17203886 | 1.00 | SLC6A5 (0.54) | SLC6A5NOD1ITGB3ITGA2BFAAH | |
| SCHEMBL19138238 | 1.00 | SLC6A5 (0.54) | SLC6A5NOD1ITGB3ITGA2BFAAH | |
| SCHEMBL9665935 | 1.00 | SLC6A5 (0.54) | SLC6A5NOD1ITGB3ITGA2BFAAH | |
| SCHEMBL19138207 | 1.00 | SLC6A5 (0.54) | SLC6A5NOD1ITGB3ITGA2BFAAH | |
| SCHEMBL9664371 | 1.00 | SLC6A5 (0.54) | SLC6A5NOD1ITGB3ITGA2BFAAH | |
| SCHEMBL13279668 | 1.00 | SLC6A5 (0.54) | SLC6A5NOD1ITGB3ITGA2BFAAH | |
| SCHEMBL20956613 | 1.00 | SLC6A5 (0.54) | SLC6A5NOD1ITGB3ITGA2BFAAH | |
| SCHEMBL19138232 | 1.00 | SLC6A5 (0.54) | SLC6A5NOD1ITGB3ITGA2BFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409517-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2024-12-12 | — | — | US | claimed |
| CN-118102889-A | Organic compound | 奇华顿股份有限公司 | 2024-05-28 | — | — | CN | claimed |
| EP-0473700-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1992-03-11 | — | — | EP | claimed |
| WO-1990014429-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1990-11-29 | — | — | WO | claimed |
| EP-4520348-A1 | CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF | Sunforest (Beijing) Biopharma Ltd (CN) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023213310-A9 | CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF | 太阳雨林(北京)生物医药有限公司 | 2025-02-20 | — | — | WO | disclosed |
| US-20240409517-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2024-12-12 | — | — | US | disclosed |
| CN-118102889-A | Organic compound | 奇华顿股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| WO-2023213310-A1 | CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF | 太阳雨林(北京)生物医药有限公司 | 2023-11-09 | — | — | WO | disclosed |
| CN-115607677-A | Compound for preventing, preventing or treating microbial infection and preparation and application thereof | 太阳雨林(北京)生物医药有限公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-114569726-B | Compound for preventing, preventing or treating microbial infection and preparation method and application thereof | 太阳雨林(北京)生物医药有限公司 | 2022-10-28 | — | — | CN | disclosed |
| CN-114788872-A | Compound for preventing, preventing or treating microbial infection and preparation and application thereof | 太阳雨林(北京)生物医药有限公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-114569726-A | Compound for preventing, preventing or treating microbial infection and preparation method and application thereof | 太阳雨林(北京)生物医药有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-10835572-B2 | Composition for external application | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2020-11-17 | — | — | US | disclosed |
| EP-3210613-A1 | COMPOSITION FOR EXTERNAL APPLICATION | Rohto Pharmaceutical Co., Ltd. (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-20170209522-A1 | Composition for External Application | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2017-07-27 | — | — | US | disclosed |
| CN-104955472-A | Fatty acid acylated amino acids for growth hormone delivery | NOVO NORDISK HEALTHCARE AG | 2015-09-30 | — | — | CN | disclosed |
| EP-0473700-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1992-03-11 | — | — | EP | disclosed |
| WO-1990014429-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1990-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10835572-B2 | Composition for external application | COL1A1, COL14A1, COL2A1 | SLC6A5 2313/4885NOD1 4192/4885ITGB3 4088/4885 |
| US-20240409517-A1 | ORGANIC COMPOUNDS | HTR3C, HTR3A, H1-0 | SLC6A5 1642/4885NOD1 1787/4885ITGB3 2141/4885 |
| US-20170209522-A1 | Composition for External Application | COL1A1, COL14A1, COL2A1 | SLC6A5 2313/4885NOD1 4192/4885ITGB3 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.